首页> 美国卫生研究院文献>Gynecologic Oncology Research and Practice >Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
【2h】

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?

机译:贝伐单抗生物仿制药会影响妇科癌症全身治疗的价值吗?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectiveBevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis inhibitors is limited. Biosimilars are large, structurally complex molecules that are intended to be highly similar to, and treat the same condition(s) as, an existing licensed or approved (reference) biologic, with no clinically meaningful differences in purity, potency and safety. This article summarizes the role of bevacizumab in the treatment paradigm of ovarian and cervical cancer. We also discuss the potential role of biosimilars to bevacizumab, which may offer more affordable options in the future treatment of gynecologic cancers.
机译:目的贝伐单抗是治疗各种癌症的重要组成部分,尽管有指南建议将其用于卵巢癌和宫颈癌,但患者使用贝伐单抗和其他血管生成抑制剂的机会有限。生物仿制药是大型,结构复杂的分子,旨在与现有的经过许可或批准的(参考)生物制剂高度相似,并具有相同的治疗条件,但纯度,效价和安全性没有临床意义上的差异。本文总结了贝伐单抗在卵巢癌和宫颈癌治疗范例中的作用。我们还将讨论生物仿制药对贝伐单抗的潜在作用,这可能在妇科癌症的未来治疗中提供更多可负担的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号